Results 61 to 70 of about 587,245 (265)

Two Birds with One Stone: Skull Base Meningioma and Jugulotympanic Paragangliomas with Somatostatin Receptor Positron Emission Tomography

open access: yesDiagnostics, 2021
We describe the case of a 74-year-old female patient previously treated with radiation therapy for a meningioma of the skull base and with surgery for a right tympanic paraganglioma.
Giorgio Treglia   +5 more
doaj   +1 more source

Somatostatin receptor subtypes: basic pharmacology and tissue distribution

open access: yes, 2004
The heptahelical receptor superfamily constitutes the largest single family of transmembrane-signalling molecules that regulate a wide range of physiological processes.
CORLETO, Vito Domenico   +4 more
core   +1 more source

Co‐activation of Selective Nicotinic Acetylcholine Receptor Subtypes Is Required for Neuroprotection against Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
ABSTRACT Beta‐amyloid peptide (Aβ)‐induced suppression of hippocampal GABAergic interneuron activity drives hyperexcitability, amyloid pathology, and cognitive impairment in Alzheimer's disease (AD), suggesting that enhancing hippocampal inhibition may be protective.
Rahmi Lee   +3 more
wiley   +1 more source

Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias

open access: yesCurrent Issues in Molecular Biology
Somatostatin is a peptide that plays a variety of roles such as neurotransmitter and endocrine regulator; its actions as a cell regulator in various tissues of the human body are represented mainly by inhibitory effects, and it shows potent activity ...
Argyrios Periferakis   +12 more
doaj   +1 more source

Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells

open access: yesJournal of Experimental & Clinical Cancer Research, 2009
Background opioid and somatostatin receptors (SSTRs) that can assemble as heterodimer were individually reported to modulate malignant cell proliferation and to favour apoptosis.
Allouche Stéphane   +4 more
doaj   +1 more source

Oral Actinomyces Species Exposure is Associated with Anxiety‐Like Behavior, Mitochondrial Remodeling, and Altered GABAergic Pathways

open access: yesAdvanced Science, EarlyView.
Oral exposure to cannabis‐associated Actinomyces species, particularly A. meyeri, is associated with anxiety‐like behavior in mice in the absence of detectable bacterial translocation or overt systemic inflammation. These findings support a potential oral‐brain metabolic axis involving candidate metabolites such as arginine and argininosuccinate ...
Tabinda Salman   +11 more
wiley   +1 more source

Somatostatin receptors in fibrotic myocardium.

open access: yesPLoS ONE
A patient with a neuroendocrine tumor and history of coronary artery disease underwent PET with 68Ga-DOTATATE PET tracer for tumor visualization.
Estibaliz Castillero   +9 more
doaj   +1 more source

Somatostatin, its receptors and analogs, in lung cancer

open access: yes, 2001
Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America. Due to increasing cigarette consumption, the incidence of the disease and resultant mortality is rising dramatically in women.
Schally, A. V.   +9 more
core   +1 more source

North American Delphi Consensus Study on Sinonasal Malignancy Survivorship Care

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Survival for patients with sinonasal cancers has improved over the past decades, but there are no dedicated survivorship guidelines for this cohort. Objective To understand experts’ priorities and perspectives on key survivorship tenets (surveillance, second tumor screening, toxicity, and symptom management).
Matheus Sewastjanow‐Silva   +18 more
wiley   +1 more source

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

open access: yesPharmaceuticals, 2019
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.
Ute Hennrich, Klaus Kopka
doaj   +1 more source

Home - About - Disclaimer - Privacy